Article info
PDFCommentary
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020
- Correspondence to Stephanie Lheureux, Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; Stephanie.Lheureux{at}uhn.ca
Citation
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020
Publication history
- Received June 11, 2020
- Accepted June 15, 2020
- First published July 9, 2020.
Online issue publication
August 03, 2020
Article Versions
- Previous version (9 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.